Core Viewpoint - Anonymous Intelligence Company Inc. has granted restricted share units and stock options to its directors and officers as part of its Equity Incentive Plan to align their interests with those of shareholders and support the company's growth [1][3]. Equity Awards Details - The company granted a total of 600,000 stock options and 790,000 restricted share units to its directors and officers [2]. - Each stock option is exercisable for one common share at an exercise price of $0.19 per share for a period of five years from the grant date [2]. Company Overview - Anonymous Intelligence Company Inc. focuses on developing decentralized network infrastructure, data storage technology, and privacy-enhancing AI tools [5]. - The company aims to empower individuals and businesses by providing confidence in technology through its innovative solutions while prioritizing user privacy and data security [5].

Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced a series of equity compensation and marketing initiatives designed to support its growth strategy and enhance market awareness.Equity Incentive GrantsOptimi announces that, pursuant to its equity incentive plan and subject to acceptance by the Canadian Securities Exchange, it ha ...

Core Viewpoint - Matador Technologies Inc. has granted 631,818 restricted share units (RSUs) to certain officers and consultants as part of its Omnibus Equity Incentive Plan, with a 12-month vesting period starting January 8, 2026 [1] Group 1 - The total number of RSUs granted is 631,818 [1] - The RSUs are part of the company's Omnibus Equity Incentive Plan [1] - The vesting period for the RSUs is set for 12 months, beginning on January 8, 2026 [1]

Core Viewpoint - Cytokinetics granted stock options and restricted stock units (RSUs) to new employees as an inducement for their employment, reflecting the company's strategy to attract talent in the biopharmaceutical sector [1][3]. Summary by Sections Stock Options and RSUs - On December 15, 2025, Cytokinetics granted stock options to purchase 21,399 shares and 14,422 RSUs to 10 new employees [1]. - The RSUs will vest over 3 years, with 40% vesting on the first anniversary, another 40% on the second anniversary, and the final 20% on the third anniversary, contingent on continued employment [2]. - The stock options have an exercise price of $62.16 per share, equal to the closing price on the grant date, and will vest over 4 years, with 1/4th vesting on the first anniversary and the remainder vesting monthly over the next 36 months [2]. Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [4]. - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive Phase 3 trial results for obstructive hypertrophic cardiomyopathy [4]. - Other products in development include omecamtiv mecarbil for heart failure with severely reduced ejection fraction, ulacamten for heart failure with preserved ejection fraction, and CK-089 for muscular dystrophy and other muscle function impairments [4].

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cygnus Metals Limited (“Cygnus” or the “Company”) advises that following management changes announced on 26 October 2025, it has today issued an aggregate of 3,000,000 additional performance rights (“Performance Rights”) to President/Chief Executive Officer, Mr Nicholas Kwong under the Company’s Omnibus Equity Incentive Plan (“Plan”). The Company also advises that, effective today, following Mr Ernest Mast’s transition from Managing Director to Non-Executive Direct ...

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - Magma Silver Corp. (TSXV: MGMA) (OTCQB: MAGMF) (FSE: BC21) (WKN: A411DV) (the "Company" or "Magma") announced that its board of directors has approved the grant of a total of 50,000 incentive stock options (the "Stock Options") to certain of its directors, officers, consultants, and employees pursuant to the Company's Stock Option Plan. Such Stock Options are exercisable into Common Shares at an exercise price of $0.27 per share for a peri ...

VANCOUVER, British Columbia, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Sable Resources Ltd. (“Sable” or the “Company”) (TSXV: SAE | OTCQB: SBLRF) is pleased to announce that the shareholders of the Company provided near unanimous approval of a new omnibus equity incentive plan (the “Equity Incentive Plan”) at the Company’s annual general and special meeting of shareholders held earlier today (the “Meeting”). All other matters advanced at the Meeting, including setting the board at five members, re-election of direc ...

Core Points - NexMetals Mining Corp. has granted annual equity incentive awards to directors, officers, employees, and consultants under its Omnibus Equity Incentive Plan [1][3] - The Board approved the grant of 332,512 restricted share units (RSUs), with 287,512 RSUs priced at $7.60 each, reflecting a 55% premium over the closing share price on November 17, 2025 [2] - An additional 45,000 RSUs were granted at a price of $8.80 each, representing a 79% premium to the closing share price [2] - The company also granted 46,600 deferred share units (DSUs) to directors at a price of $7.60 each, which will be payable in cash [3] - The equity incentive grants aim to align the interests of stakeholders with those of shareholders and support long-term retention and performance objectives [3] Company Overview - NexMetals Mining Corp. focuses on the redevelopment of previously producing copper, nickel, and cobalt resource mines in Botswana [5] - The company emphasizes governance through transparent accountability and open communication [6] - The team at NexMetals has extensive experience in mine discovery and development, with senior members averaging over 20 years in geology, engineering, operations, and project development [6]

Core Insights - CMOC Group reported record high results for 3Q25, with net profit attributable to shareholders growing 73% YoY to Rmb14.3 billion, driven by increased sales volume and prices of metal products [1] Financial Performance - In 1–3Q25, revenue decreased by 6% YoY to Rmb145.5 billion, while net profit attributable to shareholders increased by 73% YoY to Rmb14.3 billion [1] - For 3Q25, revenue fell 2% YoY but rose 4% QoQ to Rmb50.7 billion, with net profit attributable to shareholders growing 96% YoY and 19% QoQ to Rmb5.6 billion [1] - Copper and cobalt output rose 14% and 4% YoY, respectively, in 1–3Q25, meeting 86% and 80% of the firm's annual guidance [1] Sales and Pricing - Copper sales volume increased by 11% YoY, while cobalt sales volume fell by 36% YoY in 1–3Q25, primarily due to a cobalt export ban from the Democratic Republic of the Congo [1] - Average prices for copper, cobalt, molybdenum, tungsten, niobium, and phosphorus rose by 4%, 15%, 7%, 30%, 8%, and 20% YoY, respectively, in 1–3Q25 [1] Strategic Developments - The firm announced the Phase II KFM project, targeting an annual copper production capacity of 800,000 to 1 million tons, expected to start production in 2027 [2] - A significant equity incentive plan was proposed to issue 393 million H shares to retain core talent [3] Market Dynamics - Tightening supply and demand dynamics are expected to push up cobalt prices, with the DRC's cobalt quota for 2026/27 accounting for 44% of its 2024 output [4] - The company holds the highest local market quota for cobalt, which is projected to account for 32% of the total local quota and 29% of its 2024 sales volume [4] Financial Forecasts and Valuation - Earnings forecasts for 2025 and 2026 have been raised by 26.6% and 32.0%, respectively, to Rmb20.67 billion and Rmb27.25 billion [5] - A-share stock is trading at 17.4x 2025e and 13.2x 2026e P/E, while H-share stock is trading at 15.4x 2025e and 11.5x 2026e P/E [5] - Target prices for A-shares and H-shares have been raised by 41% to Rmb20.4 and HK$19.7, respectively, implying a 21.6% upside [5]

Core Points - Forte Group Holdings Inc. has granted stock options and restricted share units to certain directors, officers, and consultants, effective October 10, 2025, under its Omnibus Equity Incentive Plan [1] - The company granted a total of 1,945,000 stock options at an exercise price of $0.20 per share, which vest immediately and have a two-year term expiring on October 10, 2027 [2] - A total of 2,445,000 restricted share units were granted, with a vesting schedule that includes a statutory hold period of four months and one day from the grant date [3] Stock Options and RSUs - The stock options granted are subject to a two-year term and an immediate vesting schedule [2] - The restricted share units will vest in four equal installments over a year, with specific dates outlined for each installment [8] Insider Grants - The stock option and RSU grants to certain insiders are classified as "related party transactions" and are exempt from certain valuation and minority shareholder approval requirements due to the company's market capitalization [5] - The company believes that the immediate closing of these insider grants is necessary to improve its financial position [5] Warrant Amendments - The company announced the extension and repricing of 1,152,937 common share purchase warrants to a revised expiry date of June 19, 2027, and a revised exercise price of $0.20 [6] - The original exercise price of the warrants was $0.60, and the repricing is subject to the unanimous consent of the registered holders [6][7] - The repricing aligns with the company's capital strategy to strengthen its financial position and provide flexibility for growth initiatives [7] Company Overview - Forte Group Holdings Inc. is focused on longevity and human performance through its TRACE brand and private-label partnerships, developing alkaline and mineral-enriched beverages and nutraceutical supplements [10] - The company operates a Health Canada and HACCP-certified manufacturing facility and owns a natural alkaline spring water aquifer [10]